Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vasopressin agonists and antagonists.

M Thibonnier1

  • 1Division of Hypertension and Endocrinology, Case Western Reserve University School of Medicine, Cleveland, Ohio.

Hormone Research
|January 1, 1990
PubMed
Summary

Researchers modified the vasopressin molecule to create specific V1 vascular, V2 renal, and mixed V1/V2 analogs. New generations of vasopressin antagonists show potential for therapeutic applications, particularly for V1 vascular receptors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists.

Expert opinion on investigational drugs·2005
Same author

Molecular pharmacology and modeling of vasopressin receptors.

Progress in brain research·2002
Same author

Role of the human V1 vasopressin receptor COOH terminus in internalization and mitogenic signal transduction.

American journal of physiology. Endocrinology and metabolism·2001
Same author

Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists.

Expert opinion on investigational drugs·2001
Same author

The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists.

Annual review of pharmacology and toxicology·2001
Same author

Mediators of the mitogenic action of human V(1) vascular vasopressin receptors.

American journal of physiology. Heart and circulatory physiology·2000

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Endocrinology

Background:

  • Vasopressin is a key hormone regulating blood pressure and water balance.
  • Specific vasopressin receptor subtypes (V1 and V2) mediate distinct physiological effects.
  • Developing selective antagonists is crucial for targeted therapeutic interventions.

Purpose of the Study:

  • To review discrete structural modifications of the vasopressin molecule.
  • To present third and fourth-generation vasopressin antagonists.
  • To illustrate the potential advantages of these analogs using V1 vascular receptors.

Main Methods:

  • Structural modifications including deletions and substitutions of the vasopressin molecule.
  • Linearization of the vasopressin analog structure.
  • Evaluation of antagonist activity on V1 vascular vasopressin receptors of human platelets.

Main Results:

  • Development of specific V1 vascular, V2 renal, and mixed V1/V2 vasopressin analogs.
  • Characterization of third-generation antagonists via carboxy-terminal modifications.
  • Presentation of fourth-generation antagonists with deletions, substitutions, and linearization.

Conclusions:

  • Discrete structural modifications enable the development of selective vasopressin receptor antagonists.
  • Third and fourth-generation antagonists offer improved specificity and potential therapeutic benefits.
  • Work on V1 vascular receptors highlights the practical advantages of these novel compounds.

Related Experiment Videos